46
Participants
Start Date
September 30, 2009
Primary Completion Date
January 31, 2017
Study Completion Date
January 31, 2017
Bevacizumab
Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.
Paclitaxel
Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
University General Hospital of Alexandroupolis, Alexandroupoli
"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens
"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens
"Marika Iliadis Hospital of Athens, Dep of Medical Oncology", Athens
"Metaxa's Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology", Athens
401 Military Hospital of Athens, Athens
Air Forces Military Hospital of Athens, Athens
University Hospital of Crete, Heraklion
State General Hospital of Larissa, Dep of Medical Oncology, Larissa
"Diabalkaniko hospital, Thessaloniki", Thessaloniki
": Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki
Lead Sponsor
University Hospital of Crete
OTHER
Hellenic Oncology Research Group
OTHER